Dr. Charles Rudin from Johns Hopkins covers the work from the Lung Cancer Mutation Consortium that identified a wide range of molecular markers in patients with lung adenocarcinoma.

Dr. Charles Rudin from Johns Hopkins covers the work from the Lung Cancer Mutation Consortium that identified a wide range of molecular markers in patients with lung adenocarcinoma.